Results 61 to 70 of about 28,689 (318)

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

Nature Communications
Ruxolitinib is a potent JAK1/JAK2 inhibitor, approved for the treatment of primary myelofibrosis (PMF) patients based on the concept of inhibition of oncogenic signaling.
Sivahari Prasad Gorantla, Michael Rassner, Kirstyn Anne Crossley, Tony Andreas Müller, Teresa Poggio, Shifa Khaja Saleem, Helen Kleinfelder, Sudheer Madan Mohan Gambheer, Cornelia Endres, Sabina Schaberg, Dominik Schmidt, Gerin Prince, Irene Gonzalez-Menendez, Detlef Bentrop, Rainer Trittler, Svetlana Rylova, Dietmar Pfeifer, Geoffroy Andrieux, Leticia Quintanilla-Martinez, Anna Lena Illert, Nikolas von Bubnoff, Robert Zeiser, Justus Duyster   +22 more
doaj   +1 more source

Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model

Advanced Science, EarlyView.
Nanographene oxide (NGO) attenuates graft‐versus‐host disease (GVHD) severity by inhibiting STAT1‐mediated M1 macrophage polarization and suppressing T‐cell activation. NGO‐primed macrophages (NGO‐Mac) further enhance regulatory T‐cell induction via IL‐10. Both NGO and NGO‐Mac therapies mitigate inflammation and immune pathology, offering cell‐free and
Aaron Yu, Hyun Sung Park, Dong‐Hoon Chae, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Hyewon Lee, Sueyeon Jee, Chanwoo Kim, Soon Won Choi, Jaechul Ryu, Eun‐Hye Hur, Yunsuk Choi, Eun‐Ji Choi, Mi‐Kyung Oh, Hwa‐Yong Lee, Je‐Hwan Lee, Kyung‐Rok Yu   +18 more
wiley   +1 more source

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. [PDF]

, 2018
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance1-4. This phenomenon has been implicated in chemorefractory small cell lung cancer and resistance to targeted therapies5-8, but remains incompletely ...
A Marusyk, AD Rouillard, Amir Reza Aref, AN Hata, Anika Elise Adeni, AR Aref, Brandon Piel, C Henke, Camilla Laulund Christensen, CD Carey, Christine Anne Lydon, CL Christensen, Cloud Peter Paweletz, D Gao, D Hanahan, D Miao, D Pan, D Peng, D Roulois, DA Barbie, DA Rhodes, David Allen Barbie, Debattama Rai. Sen, Diana Miao, DJ Konieczkowski, DP Tabassum, DR Sen, EB Chuong, Evisa Gjini, Ewa Sicinska, F Perocchi, G Bindea, Gao Zhang, Hideki Terai, Hideo Baba, Hideo Watanabe, I Canadas, I Tirosh, Israel Cañadas, J Barretina, J Calbo, J Chen, Jacob Sands, JG Doench, Jong Wook Kim, JT Poirier, JW Kim, KA Hoadley, KB Chiappinelli, Kwok Kin Wong, Lynnette Marie Sholl, Marco Campisi, Masayuki Watanabe, Meenhard Herlyn, MR Junttila, NE Sanjana, O Shalem, Pablo Tamayo, Ravindra Uppaluri, Rohit Thummalapalli, RT Manguso, Russell William Jenkins, RW Jenkins, Scott Rodig, Shohei Koyama, Shunsuke Kitajima, Thanh Uyen Barbie, Tian Tian, Timothy Hagan, Tran Thai, X Wu, Y Qiao, Yanan Kuang, Yanxi Zhang, Yu Imamura, Zhi Wei   +75 more
core   +1 more source

Peritransplantation Use of Ruxolitinib in Myelofibrosis

Biology of Blood and Marrow Transplantation, 2020
Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however.
John Mascarenhas, Giulia Petrone, Alla Keyzner, Uroosa Ibrahim   +3 more
openaire   +3 more sources

Targeting HDAC and PARP Enhances STING‐Dependent Antitumor Immunity in STING‐Deficient Tumor

Advanced Science, EarlyView.
Dual HDAC and PARP inhibition restores STING signaling, enhances interferon response, and boosts antitumor immunity in STING‐deficient tumors. . Abstract The stimulator of interferon genes (STING)‐mediated innate immune pathway plays an important role in tumor immunosurveillance.
Chengzhou Mao, Weiwen Fan, Jiaqi Liu, Fangzhou Yang, Wenkai Li, Lulu Li, Zhichao Shi, Qinyuan Li, Zigao Yuan, Yuyang Jiang, Bizhu Chu   +10 more
wiley   +1 more source

Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy

Advanced Science, EarlyView.
Metabolic rewiring in cancer is mapped across glucose, amino acid, lipid, nucleotide, and mitochondrial pathways, with emphasis on immune regulation. The review integrates mechanisms linking these pathways to tumor progression and therapy resistance, and profiles nanomaterial platforms that both deliver therapeutics and actively reprogram ...
Xiaosu Zhou, Ruibing Deng, Zunde Liao, Xiaoyu Huang, Junting Huang, Hanlou Yang, Kam W. Leong, Yiling Zhong   +7 more
wiley   +1 more source

Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis

Cancer Immunology, Immunotherapy
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by marrow fibrosis, splenomegaly, constitutional symptoms and cytopenia with a proinflammatory and profibrotic cytokine phenotype involving the JAK-STAT pathway.
Sara Villar, Emmanuel Curis, Marie-Hélène Schlageter, Nelly Bosselut, Amandine Charbonnier, Marie-Thérèse Rubio, Pascal Turlure, Hélène Labussière, Jacques-Olivier Bay, Jérome Cornillon, Laure Vincent, Corentin Orvain, Jean-Jacques Kiladjian, David Michonneau, Gérard Socié, Marie Robin   +15 more
doaj   +1 more source

Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében | Diagnosis and treatment of polycythaemia vera: state of the art [PDF]

, 2016
Absztrakt A polycythaemia vera a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka neoplasia, amelyre az emelkedett vörösvérsejttömeg okozta hiperviszkozitás a jellemző.
Borbényi, Zita, Marton, Imelda, Simon, Zsófia   +2 more
core   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source